COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 4 for:    giant axonal neuropathy
Previous Study | Return to List | Next Study

Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02362438
Recruitment Status : Recruiting
First Posted : February 13, 2015
Last Update Posted : May 21, 2020
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )

Brief Summary:


- The Gigaxonin gene lets the body make a protein chemical called Gigaxonin. Nerves need Gigaxonin to work properly. Giant Axonal Neuropathy (GAN) causes a shortage of functional Gigaxonin. Nerves stop working normally in people with GAN. This causes problems with walking and sometimes with eating, breathing, and many other activities. GAN has no cure. Over time, GAN can shorten a person s life. Researchers want to see if a gene transfer treatment may help people with GAN.


- To see if a gene transfer is safe and shows potential to help people with GAN.


- People age 5 and older with GAN.


  • For 2 months participants must live full-time within 100 miles of the NIH.
  • Participants will be screened by phone and in person. They will take many tests. Some are listed below. Their medical records will be reviewed. Their caregivers may be contacted.
  • Participants will have a total of about 30 visits, weekly, monthly, and then yearly over 15 years. They will include many of the tests below.
  • Physical and nervous system exams.
  • Blood, urine, and stool samples.
  • Nerve, lung, heart, and eye tests.
  • Questionnaires.
  • MRI scans, nerve biopsies, and spinal taps. Participants will be sedated for some tests.
  • Speech, memory, muscle, and mobility tests.
  • Skin biopsy (small sample removed).
  • Participants will take many medicines. Some require intravenous lines.
  • Participants will get the gene transfer through an injection by spinal tap into their cerebrospinal fluid, which flows around the brain and spinal cord. The genes are packed in a modified virus that carries the genes to cells in their body. Participants safety is not guaranteed.

Condition or disease Intervention/treatment Phase
Giant Axonal Neuropathy Gene Transfer Drug: Intrathecal Delivery of scAAV9/JeT-GAN Phase 1

Detailed Description:

This is a non-randomized, phase I, escalating single dose study to assess the safety of the gene transfer vector scAAV9/JeT-GAN through intrathecal delivery to the brain and spinal cord of patients with Giant Axonal Neuropathy (GAN, OMIM No.256850). The primary objective of this study is to assess the safety of the vector following intrathecal delivery in 10-12 GAN patients who are five years of age or older and have mutations which result in positive cross-reactive immunological material (CRIM) status. This terminology is used in other genetic disorders with residual protein expression that would allow for immunotolerance, amenable to enzyme or gene replacement such as in Pompe disease. Mutations which could result in CRIM-positive status include missense mutations, in-frame deletions or duplications or hypomorphic mutations (such as regulatory domain mutations which are leaky such as incomplete splice site mutations). This protocol was amended to include a single GAN patient, 5 years or older CRIM negative patient ('null mutation patient'). Secondary objectives of this study are 1) to assess motor and sensory disease symptoms pre- and post-treatment, 2) to examine neuropathology in peripheral nerve biopsies in response to treatment, 3) to examine cerebrospinal fluid (CSF) and to conduct CSF studies to assess response to treatment, and 4) to assess vector shedding following vector administration. The first eligible CRIM positive patient will have a genetic diagnosis of giant axonal neuropathy, will be seven years of age or older, and will have a forced vital capacity of greater than or equal to 50 percent predicted value on pulmonary function testing. This study will be the first-in-human trial of intrathecal delivery of scAAV9/JeT-GAN. The primary endpoint will be safety, based upon adverse events and standard laboratory safety evaluations. Secondary endpoints will include clinical and physiological assessment of motor and sensory function, possible rescue of disease pathology in peripheral nerves, examination of CSF in response to treatment, and assessment of vector shedding following administration.

GAN is a chronic neurodegenerative autosomal recessive disease pathologically characterized by enlarged axons with disordered microtubules and intermediate filaments. The disease pathology is due to loss-of-function mutations in the GAN gene, which encodes the protein gigaxonin. Gigaxonin plays a major role in the maintenance of orderly and functional intermediate filament (IF) architecture, which is critical for axonal function. Onset of symptoms, usually at 3-4 years of age, generally manifests with a slightly awkward gait (sensory ataxia). In the peripheral nervous system the disease progressively affects predominantly sensory and motor nerves. By the end of the 2nd decade of life, patients typically are wheelchair dependent with limited use of the arms and little to no use of their legs. During the 2nd decade a tracheostomy or other means of ventilation, as well as a feeding tube, are often necessary. Death normally occurs in the 2nd or 3rd decade of life. There are no statistics on the incidence of the disease, but it is considered extremely rare and there are no effective treatments for the disease. Intrathecal delivery of a gene transfer vector carrying a normal copy of the GAN Gene to the spinal cord and brain offers a potentially effective treatment for GAN.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy
Actual Study Start Date : April 24, 2015
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : April 1, 2030

Intervention Details:
  • Drug: Intrathecal Delivery of scAAV9/JeT-GAN
    Intrathecal transfer of scAAV9/JeT-GAN, with escalating doses at 3.5x10^13 vg, 3.3 x higher dose of 1.2 x10^14 vg, and the 5x higher dose of 1.8 x10^14 vg and the 10x higher dose of 3.6x10^14 vg.

Primary Outcome Measures :
  1. To determine the relative safety of intrathecal administration of scAAV9/JeT-GAN in the treatment of Giant Axonal Neuropathy [ Time Frame: Following vector administration: during weeks 1-4; months 3, 6, 9, 18; and, years 1 to 15; primary initial window for safety is within the first 1 year post gene transfer. Long term safety follow up will be evaluated for up to 15 years. ]
    The primary objective is to assess the safety of the vector as the incidence of serious adverse events at least possibly related to the investigational treatment, following intrathecal administration. The safety of scAAV9/JeT-GAN, measured by quantitative and qualitative descriptive statistics of the incidence of Adverse Events. Additional safety studies include: CSF studies, blood work, MRI brain/ spine.While the primary objective is safety, this study also evaluates safety, with the primary efficacy endpoint being MFM32. Additional supporting efficacy measures of interest include: FARS, myometry, NIS, NCS, and ophthalmology evaluation.

Secondary Outcome Measures :
  1. To determine the efficacy of scAAV9-JeT-GAN, measured by improvement of pathologic, histologic, physiologic, function, and clinical markers of Giant Axonal Neuropathy [ Time Frame: post-vector administration during first four weeks, months 3, 6, 9, and 18; and years 1 to 15 ]
    Secondary objectives include:-Assessment of motor and sensory disease symptoms compared to baseline, based upon standardized testing and investigational Non Significant Risk testing methods before and after administration of the investigational agent;-Examination of neuropathology in peripheral nerve biopsies after investigational treatment, in comparison to biopsies obtained prior to treatment;-Examination of cerebrospinal fluid after investigational treatment, in comparison to CSF samples obtained prior to treatment; and-Assessment of vector shedding following IT administration.-Determine if a patient with null mutations in the GAN gene (CRIM-negative patient) can safely tolerate gene transfer with immunosuppression (to include transient corticosteroids, as well as a longer course of tacrolimus and rapamycin)All secondary outcome measures will be compared to baseline using simple descriptive statistics.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

In order to participate in this study, the subject must meet the following criteria:

  1. Age 5 years or older; however, the first patient will be no younger than 7 years of age.
  2. Genetic diagnosis of GAN: Identified mutation(s) on both copies of the GAN gene. If the mutations found are not previously reported, then predictive software tools will be utilized in order to determine the degree of certainty that the mutation is predicted to be pathogenic (disease causing). This will also be evaluated in the context of the clinical and pathological phenotype (see below).
  3. Onset of clinical signs and symptoms consistent with GAN, including at least abnormal gait, as well as physical examination findings including at least abnormal gait, abnormal sensation (proprioceptive and/ or vibration sensation and/or positive Romberg), and some quantifiable weakness on manual muscle testing examination (score of < 5/5 strength of at least one tested muscle).
  4. Men capable of fathering a child must agree to use barrier contraception (combination of a condom and spermicide) or limit activity to post-menopausal, surgically sterilized, or contraception-practicing partners, for 6 months after administration of investigational product. Women and girls of childbearing potential (and parents/ guardians for minors < 18) must agree to have urine human chorionic gonadotropin testing performed to rule out the possibility of pregnancy at each visit. Those women who are sexually active must also agree to use barrier contraception as well or limit activity to surgically sterilized or contraception-practicing partners for 3-6 months after the administration of the investigational product. This limitation is set because of the unknown risk associated with the administration of this vector genome to offspring. There is no known risk of sexual transmission of the vector.
  5. Willing and able to give informed consent if >17 years of age and assent if >7 years of age. For patients ages 7-17, parents or legal guardians must also consent to the child s participation in the study. Adults who lack capacity to consent but who have an appropriate surrogate may be included.
  6. Willingness to undergo a nerve biopsy at baseline and at 12 months after treatment.
  7. Agree to reside within 100 miles of the study site for at least 2 months following treatment (may include housing on NIH campus).


In order to participate in this study, a patient MUST NOT have the following characteristics:

  1. Pregnant or lactating patients
  2. Forced vital capacity less than or equal to 50% of predicted value
  3. Ventilator dependence to include daytime use of assisted ventilation
  4. Current clinically significant infections including any requiring systemic treatment including but not limited to Human immunodeficiency virus, Hepatitis A, B, or C, Varicella zoster virus, or HTLV-1
  5. Prior history of bacterial meningitis
  6. Unwilling to undergo lumbar puncture at baseline and up to 2 to 3 times during follow up during the first year after treatment.
  7. Clinically significant echocardiogram abnormality per PI, anesthesiologist, and cardiologist
  8. Clinically significant electrocardiogram (ECG) abnormality per PI, anesthesiologist, and cardiologist
  9. History of brain or spinal cord disease that would interfere with the LP procedures, CSF circulation, or safety assessments
  10. Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter
  11. Any prior participation in a study in which a gene therapy vector or stem cell transplantation was administered to avoid any ambiguity in the safety assessment resulting from lingering effects from a previous treatment.
  12. Participation in an IND, IDE, or equivalent clinical study in the past six months.
  13. History of or current chemotherapy, radiotherapy or other immunosuppressive therapy within the past 30 days. Corticosteroid treatment may be permitted at the discretion of the PI.
  14. Immunizations of any kind in the month prior to the study to avoid lingering immune effects that could be confusing in the safety assessment of the trial.
  15. Current use of medication (e.g., levothyroxine, vitamin A supplementation, oral contraceptive use, tetracycline, Diamox) that could potentially lead to changes in intracranial pressure
  16. Known sensitivity or adverse reaction to anesthetic medications likely to be used in the peri-operative period per the anesthesiologist s evaluation
  17. GAN subjects without quantifiable weakness or functional loss
  18. Evidence of cardiomyopathy on history, exam, or additional testing (echocardiogram or electrocardiogram) or other cardiac disease that in the opinion of the investigator would deem the subject unsafe to participate in the trial
  19. History of diabetes or clinically significant abnormality of glucose tolerance test, fasting blood sugar
  20. Positive purified protein derivative testing for tuberculosis
  21. Abnormal laboratory values considered clinically significant per the investigator:

    1. Platelet count < 100,000 / mm3
    2. Persistent leukopenia or leukocytosis (Total white blood cell count < 3,000/mm and > 12,000/mm respectively)
    3. Significant anemia [Hb <10 g/dL]
    4. Abnormal prothrombin (PT) or partial thromboplastin time (PTT) [value]
    5. Abnormal liver function tests (>1.5 X ULN or > 2 X the baseline value)
    6. Abnormal pancreatic enzymes (>1.5 X ULN or > 2 X the baseline value)
    7. Patients with renal impairment defined as urinary protein concentration greater than or equal to 0.2 g/L on 2 consecutive tests
  22. Failure to thrive, defined as:

    1. Falling 20 percentiles (20/100) in body weight in the 3 months preceding Screening/Baseline
    2. In patients below the 3rd percentile, any further drop in body weight percentile in the 3 months preceding Screening/Baseline
  23. Weight less than 17kg at Baseline to avoid additional risks from comorbidity
  24. Any anticipated need for major surgery in the next 12 18 months (including scoliosis correction surgery)
  25. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02362438

Layout table for location contacts
Contact: Carsten G Bonnemann, M.D. (301) 594-5496

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Layout table for investigator information
Principal Investigator: Carsten G Bonnemann, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Institute of Neurological Disorders and Stroke (NINDS) Identifier: NCT02362438    
Other Study ID Numbers: 150073
First Posted: February 13, 2015    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: February 19, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ):
AAVp Mediated Gene Transfer
Phase 1
Safety Study
Giant Axonal Neuropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Giant Axonal Neuropathy
Hereditary Sensory and Motor Neuropathy
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Nervous System Malformations
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Congenital Abnormalities
Genetic Diseases, Inborn